SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is at a critical inflection point as the community focuses on the upcoming launch of BlueBird 7 and the company's commitment to ramping up satellite production cadence to meet aggressive 2026 deployment targets. Investors are actively debating the impact of recent insider selling against the backdrop of significant contracted revenue and institutional backing, with sentiment split between those viewing current volatility as a strategic entry point and others expressing skepticism over execution risks.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and intense community debate after a massive surge and subsequent sharp decline, with investors actively discussing potential market manipulation and the risks of holding tokens following accusations of a rug pull. The community remains deeply divided, with some traders hunting for a bounce while others warn of a total collapse and criticize the project's circulating supply structure.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors rally around Greenland's approval of the company's increased 92.5% stake in the Tanbreez rare earth deposit, a move many believe de-risks the asset and bolsters Western mineral supply chain security. The community is actively debating potential short squeeze dynamics and arguing that the current valuation fails to fully account for the project's strategic significance and long-term earnings potential.

Daddy Darth Sidious

SIDIOUS is gaining traction alongside DARTH as part of a themed 'Daddy Darth' sector, with the community actively promoting these nano-cap tokens as speculative weekend runners. Investors are debating the risks of these low-liquidity assets while frequently rotating profits between related tokens in hopes of catching a breakout.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing intense market interest following a new executive order that fast-tracks the regulatory review process for psychedelic-based mental health treatments. Community discussions are split between excitement over potential fast-track vouchers and long-term pipeline readouts, and deep skepticism rooted in the company's past management controversies and concerns regarding potential share dilution.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is experiencing significant market attention following its latest Phase 3 trial data for retatrutide, which demonstrated substantial weight loss and A1C reduction in type 2 diabetes patients without reaching a plateau. While the company's long-term dominance in the obesity and diabetes sector remains a core talking point, investors are closely monitoring competitive pressure from Novo Nordisk and regulatory scrutiny regarding potential safety profiles.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is garnering attention as the infrastructure layer for institutional finance, highlighted by the integration of SIX Group's massive real-time equities data onto the blockchain. The community is actively debating its role in RWA tokenization and its potential to serve as the critical bridge for TradFi, while concurrently navigating broader market volatility and speculation regarding future regulatory impacts.

Rayls is a Layer-1 blockchain ecosystem designed for financial institutions to bridge traditional finance (TradFi) and decentralized finance (DeFi). Developed by Parfin, Rayls combines a public chain, private networks, and institutional privacy nodes into a unified infrastructure that supports compliant, scalable, and privacy-preserving asset tokenization and settlement. Its architecture connects regulated banks and payment systems with public DeFi liquidity while maintaining confidentiality through the Rayls Enygma privacy protocol. The network enables tokenization of real-world assets, CBDCs, and stablecoins using EVM-compatible technology, fixed USD-pegged gas fees, deterministic finality, and harmful MEV protection.

Rayls

Rayls is generating significant community conversation as investors speculate on its potential for institutional adoption in the RWA space following its recent listing on major exchanges. While some participants are actively buying on perceived price bottoms, others are debating whether the volatility and recent volume patterns signal an imminent breakout or indicate a lack of long-term stability.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending following a presidential executive order designed to fast-track FDA reviews and expand research funding for psychedelic therapies. The community is actively discussing the stock's potential for clinical acceleration, with many focused on its status as one of the few players to successfully complete two Phase 3 trials and its positioning for upcoming regulatory catalysts.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as investors weigh geopolitical risks in the Strait of Hormuz against hopes for a ceasefire, prompting discussions on whether the asset is regaining its traditional role as a safe-haven hedge. Market participants are closely analyzing options flow and institutional positioning to gauge if gold's recent price action signals a broader flight to quality amid persistent concerns over inflation and energy supply shocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC...

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofORIC Pharmaceuticals, Inc. (Oricor the Company) (NASDAQ:ORIC) for violations of the securities laws.The investigation focuses on whether the Company issued false...

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.5% - Still a Buy?

Oric Pharmaceuticals (NASDAQ:ORIC) Trading Up 6.5% - Here's Why...

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the company...

Oric Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% Higher - Time to Buy?

Oric Pharmaceuticals (NASDAQ:ORIC) Trading Up 11.6% - Here's Why...

Investors Purchase Large Volume of Oric Pharmaceuticals Call Options (NASDAQ:ORIC)

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) was the target of unusually large options trading activity on Thursday. Stock traders purchased 2,266 call options on the stock. This is an...

HC Wainwright Reaffirms Buy Rating for Oric Pharmaceuticals (NASDAQ:ORIC)

HC Wainwright reissued a "buy" rating and issued a $25.00 target price on shares of Oric Pharmaceuticals in a research note on Thursday...

<ul class="summary-bullets"><li>Jones Research maintained a ‘Buy’ rating on the stock with a $25 price target, according to The Fly.</li><li>Wedbush Securities lowered its price target to $17 from $20 but maintained an ‘Outperform’ rating.</li><li>Cantor Fitzgerald said Rinzimetostat’s efficacy appears comparable to competitor Mevrometostat from Pfizer</li></ul>Shares of Oric Pharmaceuticals (ORIC) plunged 28% on Wednesday as investors reacted to tolerability concerns tied to a higher dose of its prostate cancer drug, even as analysts said the sharp sell-off appears exaggerated.<a href="https://stocktwits.com/symbol/ORIC">ORIC shares</a> recorded their biggest intraday slump in more than four years.<h2 class="st-heading-2">Oric Selects 400 MG Dose Of Rinzimetostat</h2>On Tuesday, Oric <a href="https://stocktwits.com/news-articles/markets/equity/oric-falls-after-hours-on-safety-concerns-around-prostate-cancer-candidate/cZ7HT8GRIVz">announced</a> it selected a lower 400 mg dose of its investigational drug Rinzimetostat. In the Phase 1 trial involving patients with metastatic castration-resistant prostate cancer, the 600 mg dose showed a higher rate of side effects, dose interruptions, and discontinuations when combined with darolutamide.By contrast, the 400 mg dose demonstrated a more manageable safety profile, with mostly mild side effects and only limited severe (Grade 3) events. The company now plans to move forward with the lower dose in a global Phase 3 trial in the first half of 2026.<h2 class="st-heading-2">Analysts Say Selloff is Exaggerated</h2>Despite the sharp selloff, analysts suggest the reaction may be overdone. Jones Research noted that the data appears broadly in line with Pfizer’s competing drug Mevrometostat, while potentially offering a better safety profile, according to The Fly.The firm said the selloff ‘appears exaggerated,” pointing out that Oric’s data is still early, with only about five months of follow-up compared to nine to 10 months for Pfizer’s results. Jones &nbsp;Research maintained a ‘Buy’ rating on the stock with a $25 price target.Other firms, including Cantor Fitzgerald and Wedbush, highlighted that efficacy remains comparable. “Efficacy appears comparable to competitor Mevrometostat from Pfizer, with Rinzi showing a potentially better safety profile,” Cantor said. It has an ‘Overweight’ rating on Oric shares.<h2 class="st-heading-2">Wedbush Says Results broadly In Line With Pfizer’s Drug</h2>Meanwhile, David Nierengarten of Wedbush Securities lowered his price target to $17 from $20 while maintaining an ‘Outperform’ rating. The analyst said Oric’s Phase 1 prostate cancer results are broadly in line with Pfizer’s, even though Oric tested its drug in a sicker patient group.He added that while greater efficacy differences are ideal, better tolerability is important, especially for older patients on long-term treatment, and could influence doctors’ choices if both drugs are similarly effective.Despite the sharp selloff, retail sentiment turned ‘extremely bullish’ from ‘neutral’ a day earlier.One user said the stock has "really good upside potential"<stembedurl>http://stocktwits.com/LF5/message/649195078</stembedurl>The stock has gained more than 10% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/oric-falls-after-hours-on-safety-concerns-around-prostate-cancer-candidate/cZ7HT8GRIVz">ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Oric Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says Selloff 'Appears Exaggerated’

Oric shares tanked after the firm selected a lower 400 mg dose of its investigational drug for prostate cancer after its 600 mg dose showed a higher rate of side effects.

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says ‘Selloff Appears Exaggerated’

Equity

What's Behind The Drop In Oric Pharmaceuticals Stock Today?

Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients...

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Analyst Downgrade

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Analyst Downgrade...

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC
ORIC Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ORIC News

ORICORIC Pharmaceuticals Inc